Inhibrx Biosciences enters its August 14 earnings event carrying one of the heavier short burdens in the biotech space — short interest at nearly 23% of the free float — yet the borrow market tells a surprisingly relaxed story about the conviction behind that positioning.
Short sellers hold roughly 3.3 million shares, a level that has barely moved over the past month. But the lending dynamics undercut any squeeze narrative: availability is running at approximately 400% — meaning four shares are available to borrow for every one already lent out — and cost to borrow has drifted to just 0.48%, a multi-month low. That is a large short base parked in an extremely loose borrow market, which points more to long-standing structural skepticism than to fresh, urgent bearish conviction. The ORTEX short score has nonetheless been climbing steadily, reaching 70.8 — its highest reading in the trailing two weeks — suggesting that the composite view of positioning metrics is incrementally more bearish even if the headline short share count has eased about 2.7% on the week. Options traders are not adding much to the bearish case: the put/call ratio at 0.19 is essentially flat with its 20-day average, and well below its 52-week high of 3.99, indicating no unusual demand for downside protection heading into the print.
The bull/bear debate for INBX is fundamentally a pipeline binary rather than a valuation argument. Bulls point to the company's cash runway — reported at $186.6 million — and the proprietary protein engineering platform behind INBRX-109 and INBRX-106 as sources of long-term optionality. The only recent analyst action of note was a Stifel initiation at Buy with a $150 target in April, well below the current price of $97 — and the consensus mean target of $277.50 is significantly above where the stock trades, though the analyst data underlying that consensus is several months old and should be treated with caution. JMP Securities has held a Market Perform stance without a price target across multiple reiterations, a posture that reflects the binary nature of clinical-stage names rather than a considered valuation view. The bear thesis centers on regulatory risk and the consistent pattern of post-earnings weakness: across the four most recent earnings events, the stock fell every time — declining as much as 11% on the day and as much as 13% over the subsequent five days.
Institutional ownership adds one genuinely interesting wrinkle. Viking Global held nearly 10% of shares as of March 31 and was the largest single holder — yet Viking also liquidated over 350,000 shares in October 2025 at prices around $32, roughly one-third of where the stock now trades. That sale looks poorly timed given the subsequent rally to $97, but the firm has not exited: it remains the top institutional holder. Bank of America added over 824,000 shares in the most recent reported quarter, one of the larger incremental buys in the holder table, while Perceptive Advisors trimmed modestly and Sofinnova cut its stake by about 48,000 shares.
Today's print is ultimately a test of whether Inhibrx's clinical progress and cash position can sustain a stock that has gained 13% in a week and 5% over the past month — against a backdrop of consistent post-earnings selling and a short base that has shown no sign of covering.
See the live data behind this article on ORTEX.
Open INBX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
